{"schema_version":"1.0","type":"article","title":"New Hepatitis B Drug Approved in Japan: About One in Five Treated Trial Patients Achieved a “Functional Cure”","url":"https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care-en.md","lang":"en","date":"2026-09-27","publish_at":"2026-09-27T08:00:00+08:00","updated_at":"2026-09-27","category":"商業分析系列","topic":"商業分析系列","tags":["Hepatitis B","GSK","Hibsago","Finite treatment","GBC"],"summary":"On August 24, 2026, GSK announced that Hibsago (bepirovirsen) had been approved in Japan for eligible adults with chronic hepatitis B. The Phase III results supporting the approval had already been published in May; this development moves a finite course of treatment from trial evidence into a treatment option for a defined population.","key_points":[],"facts":[],"sections":["【01 | Identifying Suitable Patients Comes Before Assessing the Value of Finite Treatment】","【02 | Weeks 24, 48 and 72 Answer Three Different Questions】","【03 | Off-Treatment Results Put the Magnitude of Benefit Against Clear Denominators】","【04 | Finite Treatment Changes the Payment Question and Reorganizes Care】","【05 | Next-Generation Treatment Designs Aim to Broaden the Chance of Sustained Control】","【06 | A Concrete Taiwanese Capability: Hepatitis Testing and Treatment Monitoring】","【Conclusion | Approval Opens a Choice; Long-Term Value Must Be Demonstrated Through Care】","【Sources】"],"references":[],"images":[{"alt":"An antisense oligonucleotide acts on the RNA and viral-protein production pathway within a liver cell, with NA background treatment labeled separately. The viral reservoir remains in the cell nucleus, with no depiction of viral eradication or a cure checkmark.","url":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care-en/01_RNA%E8%88%87%E6%9C%89%E9%99%90%E7%99%82%E7%A8%8B_EN_v2.png"},{"alt":"Two treatment bands share a timeline labeled 0, 24, 48 and 72 weeks. The study drug ends at week 24, while NA treatment can stop at week 48 only after an eligibility assessment. HBsAg and HBV DNA testing at week 72 assesses the outcome after treatment withdrawal.","url":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care-en/02_%E6%B2%BB%E7%99%82%E8%88%87%E8%BF%BD%E8%B9%A4%E6%99%82%E9%96%93%E8%BB%B8_EN_v2.png"},{"alt":"Two bar-chart panels use the same scale, showing B-Well 1 at approximately 20% versus 0% and B-Well 2 at approximately 19% versus 0%. Each bar retains the number reaching the endpoint and its original denominator, with notes identifying the week-72 endpoint and at least 24 weeks of off-treatment observation.","url":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care-en/03_%E5%85%A9%E8%A9%A6%E9%A9%97%E5%81%9C%E8%97%A5%E5%BE%8C%E7%AB%AF%E9%BB%9E_EN_v2.png"},{"alt":"Three equally sized scenes connect testing and clinical assessment, a treatment calendar with payment documents, and follow-up blood sampling. They show the coordination needed for finite treatment, without prices, guaranteed treatment withdrawal or revenue growth.","url":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care-en/04_%E6%9C%89%E9%99%90%E7%99%82%E7%A8%8B%E5%AE%8C%E6%95%B4%E7%85%A7%E8%AD%B7_EN_v2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care-en/01_RNA%E8%88%87%E6%9C%89%E9%99%90%E7%99%82%E7%A8%8B_EN_v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-27）。New Hepatitis B Drug Approved in Japan: About One in Five Treated Trial Patients Achieved a “Functional Cure”。https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-27-hibsago-finite-hbv-care.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}